Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August

Executive Summary

Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist

You may also be interested in...



Reanalyzed MERIT Data Suggests Selzentry Efficacy Matches HIV Standard Of Care

Enhanced Trofile assay reveals previous data included patients with HIV variants who should have been excluded, Pfizer and Monogram Biosciences report at ICAAC.

AIDS Drug Rebates Were “Largest Driver” Of ADAP Budget Growth In 2007

Manufacturer rebates on AIDS drugs now account for 18 percent of the overall budget for AIDS Drug Assistance Programs, compared to 6 percent in the mid-1990s, according to the National ADAP Monitoring Project's annual report, released April 8

AIDS Drug Rebates Were “Largest Driver” Of ADAP Budget Growth In 2007

Manufacturer rebates on AIDS drugs now account for 18 percent of the overall budget for AIDS Drug Assistance Programs, compared to 6 percent in the mid-1990s, according to the National ADAP Monitoring Project's annual report, released April 8

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel